<DOC>
	<DOC>NCT01442155</DOC>
	<brief_summary>This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer. Data were collected from each participant for up to 36 months or until disease recurrence.</brief_summary>
	<brief_title>An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Adult participants, &gt;/= 18 years of age Treatment in line with the currently approved indication in the Summary of Product Characteristics Contraindications according to the current Summary of Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Adjuvant setting</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
</DOC>